Instructional Course - Requires Course Pass, Additional Registration Required

Instructional Course

058IC - Management of Common Dilemmas in Prostate Cancer Diagnosis, Staging & Treatment

Sunday, May 20
4:00 PM - 6:00 PM
Location: MCC WEST, 2006

We will discuss common PSA dilemmas: 1. Who should be screened? 2. What is the role of MRI in biopsy naive and men with prior negative biopsy? 3. What other markers can be used to determine whether biopsy or rebiopsy is warranted? 4. Whats the optimal biopsy strategy: Transrectal, transperineal, MRI-cognitive, MRI fusion? 5. Discuss Active Surveillance, Rad Px, XRT and focal therapy pros and cons for PSA-detected cancer. 6. What is role of adjuvant v. salvage XRT post-RP? 7. Review new PET scans for biochemically recurrent disease after RP or XRT. 8. Discuss roles of ADT, chemotherapy, and other agents (PARP inhibitors, vaccines, immunooncologic agents) in men with advanced and metastatic disease.

Learning Objectives:

Gerald L. Andriole

Washington University in Saint Louis

Gerald L. Andriole, Jr., MD, is the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center and Washington University School of Medicine in St. Louis, Missouri.

Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed urology residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland.

Dr. Andriole has over 30 years of consistent contributions in the areas of BPH and prostate cancer screening and prevention research. He has contributed well over 350 peer-reviewed publications and serves on the editorial boards of several prestigious journals. He is Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and PI of the NIDDK Multidisciplinary Approach to Urologic Pelvic Pain (MAPP) and Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). He was Chairman of the Steering Committee of the REDUCE Prostate Cancer Prevention Trial as well as PI of the NIDDK Medical Therapy of Prostatic Symptoms (MTOPS) BPH trial, and of the NIDDK Complementary and Alternative Medicine for Urinary Symptoms (CAMUS) study. He is a member of the American Urological Association, American Association for Cancer Research, the American Society of Clinical Oncology, American Surgical Association, the American Association of Genitourinary Surgeons and the Clinical Society of Genitourinary Surgeons, among other societies.

Presentation(s):

Send Email for Gerald Andriole

Anthony D'Amico

Brigham and Womens Hospital and Dana Farber Cancer Institute

Anthony D’Amico is the Eleanor Theresa Walters Distinguished Chair and Chief of Genitourinary Radiation Oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital.

Dr. D’Amico is an internationally known expert in the treatment of prostate cancer and has defined combined modality staging, which is used to select patients with localized prostate cancer for specific surgical or radiotheraputic treatment options. He is the principal investigator of several federally funded grants that support his investigations in Image Guided Therapy for early stage prostate cancer, drug development for advanced stage prostate cancer, and clinical trials that are aimed at defining future management strategies for men with prostate cancer.

Dr. D’Amico has over 300 peer reviewed original publications and editorials, and his teaching contributions include his position as Co-director of the Harvard Combined Residency in Radiation Oncology, Master of the Oliver Wendell Holmes Society at Harvard Medical School, editorial board member of 6 scientific journals, expert reviewer for 14 Journals including the New England Journal of Medicine and the Journal of the American Medical Association and editor of four textbooks on the management of prostate cancer.

Dr. D’Amico has been awarded the Best Doctor in America award annually since 2009 for his work in prostate cancer, is the 2012 Harvard Medical School Arnold P. Gold Awardee for Humanism in Medicine and the recipient of the Harvard Medical School Class of 2014, 2015 and 2016 Career Advising and Mentoring Faculty Teaching Award in addition to the 2015-2016 Morton M. Kligerman Award provided by the Hospital of the University of PA.

Presentation(s):

Send Email for Anthony D'Amico

Adam Kibel

Harvard University

Adam S. Kibel, MD is Chief of Urologic Surgery at both the Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston, Massachusetts. In addition, he is Elliot Carr Culter Professor of Surgery at Harvard University School of Medicine. Chairman of the Harvard Program in Urology Residency Program and Co-Leader of the Prostate Cancer Program for Dana Farber/Harvard Cancer Center. Dr Kibel received his undergraduate and medical degrees from Cornell University, completed his urology residency at the Harvard Urology Program, and his fellowship at the Brady Urologic Institute at Johns Hopkins in Baltimore, Maryland.

Dr. Kibel’s practice focused on minimally invasive treatments for urologic cancers. With over 190 peer reviewed publications, Dr Kibel’s research focuses on the identification of molecular markers of urologic tumors, integration of systemic agents earlier in the disease process and improved imaging of patients with urologic malignancies. His research has been supported by the National Cancer Institute, American Cancer Society, American College of Surgeons, and the American Foundation for Urologic Disease.

Presentation(s):

Send Email for Adam Kibel

A. Oliver Sartor

Tulane Medical School

Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 350 articles and book chapters and led multiple national and international clinical trials as either a principal investigator or co-principal investigator. In particular he has helped to lead pivotal trials leading to FDA approval for samarium-153 EDTMP, radium-223, and cabazitaxel. He has lectured widely, and at last count has given invited lectures in 33 countries.

He is currently the Medical Director of the Tulane Cancer Center and serves as the Laborde Professor for Cancer Research at Tulane Medical School with appointments in both the Medicine and Urology Departments.

He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is currently Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG. He is also currently a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology).

Presentation(s):

Send Email for A. Oliver Sartor


Assets

058IC - Management of Common Dilemmas in Prostate Cancer Diagnosis, Staging & Treatment



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Management of Common Dilemmas in Prostate Cancer Diagnosis, Staging & Treatment